Articles related to ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)

A rapid review found that ADHD stimulant misuse declined in several recent US surveys, particularly among younger adults, although millions continued to report misuse. Evidence linked frequent misuse with polysubstance use, while long-term health consequences remain poorly characterized.

The FDA approved centanafadine for ADHD in adults and children aged 6 years and older, introducing the first approved norepinephrine, dopamine, serotonin reuptake inhibitor for the disorder. Approval was based on phase 3 trial results and regulatory review.

Video-based ADHD prescribing increased substantially following Australia’s permanent telehealth reforms, with ADHD consultations showing greater virtual adoption than other psychotropic prescribing categories. Observational findings describe utilization patterns but do not establish causality.

Genetic analyses of nearly 80,000 infants identified variants associated with toddler activity levels and other early behavioral traits. Several of these genetic signals overlapped with those previously linked to ADHD and autism, although the findings do not establish causality.

Primary care physicians increasingly inherit adult ADHD stimulant prescriptions amid specialist shortages and medication supply disruptions. Expert guidance highlights diagnostic verification, monitoring, and risk-assessment considerations without establishing a single standardized approach.

Youth with ADHD and comorbid ASD showed distinct medication patterns and greater psychiatric burden in a large EHR cohort. The observational findings did not establish causal treatment effects.